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ABSTRACT
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in
postmenopausal women with low BMD (NCT00896532). Herein, we report the study extension evaluating 24 months of treatment with
romosozumab, discontinuation of romosozumab, alendronate followed by romosozumab, and romosozumab followed by denosumab.
Postmenopausal women aged 55 to 85 years with a lumbar spine (LS), total hip (TH), or femoral neck T-score–2.0 and–3.5 were enrolled and
randomly assigned to placebo, one of ﬁve romosozumab regimens (70mg, 140mg, 210mg monthly [QM]; 140mg Q3M; 210mg Q3M) for
24 months, or open-label alendronate for 12 months followed by romosozumab 140mg QM for 12 months. Eligible participants were then
rerandomized 1:1 within original treatment groups to placebo or denosumab 60mg Q6M for an additional 12 months. Percentage change from
baseline in BMD and bone turnover markers (BTMs) at months 24 and 36 and safety were evaluated. Of 364 participants initially randomized to
romosozumab, placebo, or alendronate, 315 completed 24 months of treatment and 248 completed the extension. Romosozumab markedly
increased LS and TH BMD through month 24, with largest gains observed with romosozumab 210mg QM (LS¼ 15.1%; TH¼ 5.4%). Women
receiving romosozumab who transitioned to denosumab continued to accrue BMD, whereas BMD returned toward pretreatment levels with
placebo. With romosozumab 210mg QM, bone formation marker P1NP initially increased after treatment initiation and gradually decreased to
below baseline by month 12, remaining below baseline through month 24; bone resorption marker b-CTX rapidly decreased after treatment,
remaining below baseline through month 24. Transition to denosumab further decreased both BTMs, whereas after transition to placebo, P1NP
returned tobaseline andb-CTX increased abovebaseline. Adverse eventswerebalancedbetween treatment groups throughmonth36. Thesedata
suggest that treatment effects of romosozumab are reversible upon discontinuation and further augmented by denosumab. © 2018 The Authors
Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.
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Introduction
Osteoporosis is a disorder of low bone mass and impairedbone strength resulting in an increased risk of fracture.(1)
Sclerostin is an osteocyte-derived inhibitor of bone formation
and stimulator of bone resorption.(2) In animalmodels, inhibition
of sclerostin improves bone structure and increases or normal-
izes bone mass and bone strength.(3–5)
Romosozumab is a humanized anti-sclerostin antibody that
stimulates bone formation and decreases bone resorption.(6) The
ﬁrst 12 months of this phase 2 study in postmenopausal women
with low bonemass evaluated the efﬁcacy and safety of different
romosozumab doses (70mg, 140mg, and 210mg) administered
by subcutaneous (s.c.) injection at 1- or 3-month intervals to
identify the optimal romosozumab regimen.(7) The higher doses
of romosozumab (140mgor 210mg) administeredmonthly (QM)
produced greater increases in bone mineral density (BMD) than
treatment with the other romosozumab regimens, and bymonth
6, 210mgromosozumabQMincreased lumbar spineBMDgreater
than alendronate or teriparatide.(7) In postmenopausal women
with osteoporosis, romosozumab 210mg QM for 12 months
reduced the risk of new vertebral and clinical fractures.(8) In
another study in postmenopausal women with a fragility
fracture,(9) romosozumab 210mg QM versus alendronate
70mg weekly (QW) for 12 months followed by open-label
alendronate 70mgQWinboth treatment arms reduced the riskof
newvertebral fracture atmonth 24 and clinical, nonvertebral, and
hip fractures at the time of the primary analysis.
This report describes the results of the continuation of the
phase 2 study in which patients received romosozumab or
alendronate/romosozumab for 24 months followed by
12 months of placebo or denosumab (Fig. 1). We evaluated
the effects of romosozumab treatment up to 24 months
(focusing on the 210mg QM dose that was evaluated in the
phase 3 studies(8,9)), the discontinuation of romosozumab, and
switching between therapies (24 months of romosozumab
followed by 12months of denosumab or placebo and 12months
of alendronate followed by 12 months of romosozumab,
followed by 12 months of denosumab or placebo). Thus, this
study investigates the effects of several possible treatment
sequences on surrogate endpoints and gives information about
their consequences.
Materials and Methods
Study design
In this phase 2, international, multicenter, randomized, placebo-
controlled, parallel group study, ambulatory postmenopausal
women, aged 55 to 85 years with low bone mass (T-score –2.0
at the lumbar spine, total hip, or femoral neck and–3.5 at each
of the three sites) andwhowere not at high risk for fracture were
enrolled. Key exclusion criteria have been described(7) and are
provided in Supplemental Methods.
As previously published,(7) we enrolled 419 women at 28
study centers in Argentina, Austria, Belgium, Canada, Denmark,
Spain, and the United States. A total of 364 of the women were
randomly assigned to one of ﬁve dosing regimens of s.c.
romosozumab (70mg, 140mg, or 210mg QM, or 140mg or
210mg every 3 months [Q3M]) or to one of two open-label
comparators (70mg of oral alendronate QW or 20 mg of s.c.
teriparatide daily) (Fig. 1).(7) The remaining 52 women were
randomly assigned to a group that received placebo injections
QM or Q3M.
The randomization was performed by means of an interactive
voice-response system according to a schedule prepared by the
Fig. 1. Study schema. Administration of placebo and the various romosozumab doses was blinded, whereas alendronate and teriparatide were
administered in an open-label fashion. All participants were instructed to take calcium (1 g) and vitamin D (800 IU) daily. Primary outcome measure
was the percent change from baseline at month 12 in BMD at the lumbar spine for individual romosozumab groups and pooled placebo arms.(7)
aParticipants randomized to the placebo and romosozumab arms continued with their assigned treatment for an additional 12 months. bParticipants
initially randomized to receive open-label alendronate started receiving romosozumab 140mg QM at month 12. cParticipants initially randomized to
receive teriparatide stopped the study at month 12 and were not included in the present analysis. ALN¼ alendronate; QM¼ every month; Q3M¼ every
3 months; Q6M¼ every 6 months; QW¼ every week; QD¼ every day; SC¼ subcutaneous; TPTD¼ teriparatide.
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sponsor before initiation of the study. In the romosozumab and
placebo groups, participants, study-site investigators, and study
personnel were not aware of the study drug (romosozumab or
placebo) and dose but were aware of the dosing schedule (QM
or Q3M). Placebo groups received doses at the same frequency
as the counterpart romosozumab groups.
Upon completion of the ﬁrst 12 months, women in the
romosozumab and placebo groups continued their assigned
treatment for an additional 12 months (Fig. 1). Women in the
alendronate group were transitioned to receive romosozumab
140mg s.c. QM for an additional 12 months, and women in the
teriparatide group ended study participation.
At the end of 24 months, eligible consenting participants were
rerandomized (1:1)within their original treatmentgroup todouble-
blind treatment with placebo or denosumab 60mg (Amgen Inc.,
Thousand Oaks, CA, USA) every 6 months (Q6M) for 12 months
(Fig. 1). Studyparticipantswereeligible for theextension if theyhad
no contraindications for denosumab treatment, including hypo-
calcemia or hypersensitivity to denosumab; had not sustained a
clinical vertebral fracture or fragility fracture of the wrist, humerus,
hip, or pelvis; and did not have a decrease in BMD of 7.0% from
baseline during the initial 24-month treatment phase of the study.
Throughout the study, all women were instructed to take calcium
(1g) and vitamin D (800 IU) daily.
The study protocol was approved by the ethics committee or
institutional review board for each center, and the study was
conducted in accordance with International Conference on
Harmonization guidelines on Good Clinical Practice and the
principles of the Declaration of Helsinki. All participants
provided written informed consent. This trial is registered at
ClinicalTrials.gov, number NCT00896532.
Study procedures
BMD was measured at the lumbar spine and proximal femur by
means of dual-energy X-ray absorptiometry at baseline, month
3, and every 6 months thereafter, and at the 1/3 radius at
baseline and annually. BioClinica (Princeton, NJ, USA, previously
known as Synarc) analyzed the scans and provided quality
control of the scanners and the individual scans.
Blood was collected for serum chemistry, hematology, and
determination of bone turnover marker levels. Levels of the
bone-formation marker P1NP and the bone-resorption marker
b-CTX were determined as previously described for the ﬁrst
12 months(7) and then at months 12 (þ1 day), 13, 14, 15, 18, 21,
24, 27, 30, and 36. Serum levels of anti-romosozumab antibodies
were assessed at baseline and months 15, 18, 21, 24, and 27.
Samples were tested for romosozumab neutralizing activity in
vitro as described.(7)
Adverse eventswere collected as observed by the investigator
or reported by subjects.
Study outcomes
The primary endpoint was the percentage change from baseline
in BMD at the lumbar spine after 12months of treatment. Results
for all enrolled participants through month 12 have been
reported by McClung and colleagues.(7) This report describes
BMD, bone turnover markers, and safety results with up to
24 months of romosozumab therapy and after transition to
denosumab or placebo for 12 months. The responses to the
romosozumab 210mg QM dose will be emphasized because
this dose has been evaluated in phase 3 studies.(8,9)
Statistical analysis
Participants initially randomized to all arms except to the
teriparatide arm were included in the month 24 analysis. All
participants in the two placebo dose groups (QM andQ3M)were
pooled as one group for comparison to the other treatment
groups. Details of statisticalmethods used for the ﬁrst 24months
of this study are described in McClung and colleagues(7) and are
provided in Supplemental Methods.
Participants rerandomized at month 24 were included in the
month 36 analysis, and all endpoints are summarized descriptively.
Analysis of the percentage change frombaseline in BMD and bone
turnover markers included all participants who had undergone
randomization, hadabaselinevalue, andhadamonth24value and
at least one subsequent measurement. Percentage changes in
BMD from baseline to month 36 are presented with means and
95% conﬁdence intervals (CIs), and percentage changes in BMD
frommonth24 tomonths 30 and36arepresentedwithmeans and
standard deviation. Percentage changes in P1NP and b-CTX from
baseline or month 24 to months 27, 30, and 36 are presented with
medians and interquartile ranges.
Safety analysis included all participants who underwent
randomization and received at least one dose of a study drug
during the ﬁrst 12 months of the study and received at least one
dose of blinded denosumab or placebo from months 24 to 36.
Safety endpoints included the incidence and severity of adverse
events; changes from baseline in vital signs, laboratory values,
and electrocardiographic variables; and the incidence of the
formation of anti-romosozumab antibodies.
Results
Participant disposition
A total of 419 women were enrolled into the study. Participants
initially randomized to receive teriparatide stopped the study at
month 12 and were not included in the present analysis.
Participant disposition through month 36 is shown in Fig. 2. Of
the 364 participants initially randomized (excluding the
teriparatide arm), 315 (87%) completed the ﬁrst 24 months
and 49 (13%) withdrew from the study before completing the
month 24 visit. The most common reasons for study discontin-
uation were consent withdrawn (22 [6%] participants) and
adverse event (19 [5%] participants). Forty-eight of the
52 women in the romosozumab 210mg QM group completed
the 24-month study.
A total of 260 of the 315 participants who completed the ﬁrst
24 months of the study were eligible and consented to be
randomized in thedenosumabextensionphase (131, placebo; 129,
denosumab) (Fig. 2). Of these, 248 (95%) completed the extension
phase (Fig. 2).Of the12participantswhodiscontinuedstudyduring
the extension phase (n¼ 8, placebo; n¼ 4, denosumab), 2 did so
because of an adverse event (both in the placebo group). Of the 48
women in the romosozumab 210mg QM group who completed
24 months, 8 chose not to take part in the third study year. The
remainder were randomized to receive placebo (n¼ 20) or
denosumab (n¼ 20) during the denosumab extension.
Baseline demographics
Baseline demographic and key characteristics for participants in
the ﬁrst 24 months of the study were balanced across the
randomized arms (Supplemental Table S1). Among all partic-
ipants, the mean age was 67 years, 87.4% of participants were
white, and the mean baseline BMD T-scores at the lumbar spine,
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total hip, femoral neck, and 1/3 radius were –2.29, –1.56, –1.95,
and –2.01, respectively. Baseline demographic and key charac-
teristics for participants who entered the 12-month denosumab
extension were also balanced across the placebo and denosu-
mab arms (Table 1).
Efficacy
BMD
At month 24, the largest gains in BMD from baseline were
observed with romosozumab 210mg QM. At the lumbar
spine, BMD increased by 11.3% at month 12 and by 15.1% at
month 24; at the total hip and femoral neck, BMD increased
by 4.1% and 3.7% at month 12, and by 5.4% and 5.2% at
month 24, respectively (all p 0.01 versus placebo) (Fig. 3A,
C, Supplemental Fig. S1A, and Supplemental Tables S2–4).
Signiﬁcant gains in BMD from baseline at the lumbar spine,
total hip, and femoral neck were also observed at month 24
with the other romosozumab treatment groups (all p 0.01
versus placebo) (Supplemental Tables S2–4). In the group
switching from alendronate to romosozumab 140mg QM,
BMD at the lumbar spine, total hip, and femoral neck
increased from baseline by 4.0%, 1.9%, and 1.3%, respec-
tively, at month 12, and by 9.0%, 2.6%, and 2.6% at
month 24 (Fig. 3B, D, Supplemental Fig. S1B, Supplemental
Tables S2–4). BMD at the 1/3 radius at month 24 remained
comparable to placebo in all treatment groups and had
decreased modestly compared with the original baseline
(romosozumab 210mg QM, –1.3%; placebo, –1.4%) (Fig. 3E,
F, Supplemental Table S5).
Participants who had received romosozumab 210mg QM for
24 months and transitioned to denosumab during the extension
continued to accrue BMDbetweenmonth 24 andmonth 36, with
additional mean gains of 2.6% at the lumbar spine, 1.9% at the
total hip, and 1.4% at the femoral neck, as well as 0.4% at the 1/3
radius (Fig. 3A, C, E, Supplemental Fig. S1A, Supplemental
Table S6). Over the full 36 months of therapy, the average
increases in BMDwere 19.4% at the lumbar spine and 7.1% at the
total hip. For all romosozumab doses combined, transition to
denosumab for 12 months also resulted in additional mean BMD
gains at the lumbar spine (3.6%), total hip (2.2%), femoral neck
(1.5%), and 1/3 radius (0.9%) frommonths 24 to 36 (Supplemental
Table S6). Similar results were observedwith denosumab therapy
in the alendronate/romosozumab group (Fig. 3B, D, and F,
Supplemental Fig. S1B, Supplemental Table S6), except that no
gainswereobserved at the 1/3 radius. In contrast, BMD in the total
hip decreased by 5.4%, returning to the pretreatment level, and
lumbar spine BMD decreased by 9.3% but remained above
baseline in participantswho receivedplacebo for 12months after
stopping romosozumab 210mg QM.
Enrolled
n = 419 M
onth 0 – 24
Placeboa
n = 52
Romosozumab
70 mg QMb
n = 51
Romosozumab
140 mg QMb
n = 51
Romosozumab
210 mg QMb
n = 52
Romosozumab
140 mg Q3Mb
n = 54
Romosozumab 
210 mg Q3Mb
n = 53
ALN 70 mg QWc
n = 51
TPTD 20 µg QDd
n = 55
Discontinued
n = 6e
Discontinued
n = 12e
Discontinued
n = 8e
Discontinued
n = 4e
Discontinued
n = 8e
Discontinued
n = 5e
Discontinued
n = 6e
Discontinued
n = 9e
Completed
n = 46d
Completed
n = 45
Completed
n = 48
Completed
n = 46
Completed
n = 48
Completed
n = 43
Completed
n = 39
Completed
n = 46
Discontinued
n = 1g
Completed
n = 17
Discontinued
n = 0g
Discontinued
n = 5g
Discontinued
n = 2g
Discontinued
n = 2g
Discontinued
n = 2g
Completed
n = 18
Completed
n = 88
Completed
n = 88
Completed
n = 18
Completed
n = 19
Romosozumab/
Placebo
n = 93
Romosozumab/
Denosumab
n = 90
ALN/Romosozumab/
Placebo
n = 20
ALN/Romosozumab/
Denosumab
n = 21
Placebo/
Placebo
n = 18
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Denosumab
n = 18
Discontinued
n = 55f
E
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M
onth 24 – 36 
Fig. 2. Disposition of initially randomized participants during the ﬁrst 24months of the study and disposition of participants rerandomized atmonth 24.
Participants were randomized 1:1:1:1:1:1:1:1 to the ﬁrst 24 months of treatment. Administration of placebo and the various romosozumab doses was
blinded, whereas alendronate and teriparatide were administered in an open-label fashion. At month 24, participants were rerandomized (1:1) within
treatment group to placebo or denosumab (60mg s.c. Q6M) for 12months. aAt month 12, participants initially randomized to receive placebo continued
to receive placebo up tomonth 24. bAtmonth 12, participants initially randomized to receive a speciﬁc dose and schedule of romosozumab continued to
receive their assigned treatment up to month 24. cAt month 12, participants initially randomized to receive open-label alendronate were transitioned to
receive romosozumab 140mgQM treatment for 12months, up tomonth 24. dParticipants initially randomized to receive teriparatide (gray box) stopped
the study at month 12 and were not included in the present analysis. eCumulative number of participants who discontinued the study during the ﬁrst
24 months. fParticipants were either ineligible for randomization or did not provide consent. gNumber of participants who discontinued the study
between month 24 and month 36. ALN¼ alendronate; QM¼ every month; Q3M¼ every 3 months; QW¼ every week; QD¼ every day;
SC¼ subcutaneous; TPTD¼ teriparatide.
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Bone turnover markers
In participants who received romosozumab 210mg QM, rapid
increases in the bone formation marker P1NP were observed
after the initial dose (Fig. 4A). This increase was transitory. Values
gradually decreased and were below baseline by month 12 and
remained below baseline through month 24 (Fig. 4A, Supple-
mental Table S7). While most marker measurements were
obtained predose, the one postdose measurement at
12 monthsþ 1 week showed a small, transitory increase in
P1NP compared with the predose measurement 1 week earlier
(Supplemental Table S7).
Levels of the bone resorptionmarker b-CTX rapidly decreased
from baseline in participants receiving romosozumab 210mg
QM after the ﬁrst dose and remained below baseline through
month 24 (Fig. 4B). Generally, similar responses were noted in
the other treatment groups (Supplemental Table S8). For all
doses of romosozumab evaluated, a transitory decrease in b-
CTX was observed 1 week after the month 12 dose.
In participants treated with alendronate, P1NP and b-CTX
were reduced from baseline in the ﬁrst year (Fig. 4C, D,
Supplemental Tables S7 and S8). Both markers increased after
transition to romosozumab 140mg QM but remained below
baseline through month 24 (Fig. 4C, D, Supplemental Tables S7
and S8).
Frommonths 24 to 36, both P1NP and b-CTX levels decreased
in participants who transitioned from romosozumab 210mgQM
to denosumab. In participants who transitioned to placebo,
P1NP levels gradually returned to pretreatment levels (Fig. 4A,
Supplemental Table S9). b-CTX levels initially increased rapidly
and substantially above baseline after romosozumab
discontinuation and remained above baseline at month 36
(Fig. 4B, Supplemental Table S10). Similar results were observed
in the other romosozumab treatment groups (Supplemental
Tables S9 and S10).
When participants treated with alendronate followed by
romosozumab 140mg QM transitioned to denosumab, both
P1NP and b-CTX levels decreased and remained low through
month 36 (Fig. 4C, D, Supplemental Tables S9 and S10). In
participants who transitioned to placebo, both P1NP and b-CTX
levels increasedslowly towardbaselinebut remainedbelowbaseline
through month 36 (Fig. 4C, D, Supplemental Tables S9 and S10).
Safety
In the ﬁrst 24 months of the study, the subject incidences of
adverse events and serious adverse events in the placebo group,
the romosozumab 210mg QM group, and the combined
romosozumab groups were similar (Table 2). Serious adverse
events reported in more than 1 participant in the combined
romosozumab treatment groups were osteoarthritis, pneumo-
nia, appendicitis, and breast cancer. Cardiovascular serious
adverse events were investigator reported and collected using
standard safety reporting procedures. Serious adverse events
falling under cardiac, vascular, or nervous system disorders
through month 24, and at month 36, were comparable between
the treatment groups.
One fatal adverse event in the placebo group and 1 in the
romosozumab (70mgQM)groupoccurred in theﬁrst 12months.(7)
No additional fatal adverse events occurred through month 24.
Two subjects experienced fragility fractures, one each in the
placebo group and the romosozumab 210mgQMgroup (Table 2).
Table 1. Baseline Demographic and Clinical Characteristics of Participants Rerandomized at Month 24
Initially
randomized Placeboa Romosozumaba Alendronate/romosozumaba,b Alla
Rerandomized
Placeboc
(N¼ 18)
Denosumab
60mg Q6Mc
(N¼ 18)
Placeboc
(N¼ 93)
Denosumab
60mg Q6Mc
(N¼ 90)
Placeboc
(N¼ 20)
Denosumab
60mg Q6Mc
(N¼ 21)
Pooled
placeboc
(N¼ 131)
Denosumab
60mg Q6Mc
(N¼ 129)
Age, mean years
(SD)
69.3 (7.4) 64.2 (4.1) 66.2 (6.5) 66.8 (6.5) 66.6 (5.6) 67.0 (6.3) 66.7 (6.5) 66.5 (6.2)
White 17 (94.4) 14 (77.8) 79 (84.9) 76 (84.4) 19 (95.0) 18 (85.7) 115 (87.8) 108 (83.7)
BMD T-score, mean (SD)
Lumbar spine 2.27
(0.65)
2.22 (0.58) 2.35
(0.66)
2.29 (0.74) 1.82
(0.62)
2.37 (0.54) 2.25 (0.67) 2.29 (0.69)
Total hip 1.36
(0.62)
1.15 (0.62) 1.51
(0.61)
1.68 (0.61) 1.54
(0.62)
1.49 (0.72) 1.49 (0.61) 1.57 (0.65)
Femoral neck 1.72
(0.65)
1.66 (0.50) 1.94
(0.53)
2.05 (0.55) 1.88
(0.53)
1.84 (0.69) 1.90 (0.55) 1.96 (0.58)
1/3 radius 1.81
(1.00)
1.71 (0.90) 1.95
(1.00)
2.09 (0.98) 2.06
(0.76)
2.09 (1.20) 1.95 (0.96) 2.03 (1.01)
Fracture history, n (%)
Yes 7 (38.9) 6 (33.3) 23 (24.7) 27 (30.0) 7 (35.0) 8 (38.1) 37 (28.2) 41 (31.8)
Serum P1NP
(mg/L), median
(IQR)
38 (34, 45) 52 (46, 59) 52 (41, 64) 50 (38, 61) 45 (39, 55) 52 (42, 58) 49 (39, 62) 51 (40, 61)
Serum b-CTX
(ng/L), median
(IQR)
384 (312,
573)
504 (378, 673) 518 (396,
688)
536 (381, 661) 423 (328,
561)
558 (429, 616) 486 (362,
649)
535 (388, 651)
Q6M¼ every 6 months; BMD¼bone mineral density; IQR¼ interquartile range; QM¼ every month.
N¼number of participants randomized into the denosumab extension phase of the study.
aRandomized treatment group up to month 24.
bParticipants initially randomized to receive alendronate started receiving romosozumab 140 mg QM at month 12.
cRandomized treatment group for the extension phase.
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Fig. 3. Percentage change from baseline in BMD at the lumbar spine (A, B), total hip (C, D), and 1/3 radius (E, F) through month 36. Results include only
participants who had received romosozumab 210mg QM (n¼ 40) for 24 months and were then rerandomized (1:1) to receive denosumab 60mg Q6M
(n¼ 20) or placebo Q6M (n¼ 20) for another 12 months; participants who had received placebo (pooled) (n¼ 36) for 24months and were rerandomized
(1:1) to receive denosumab 60mgQ6M (n¼ 18) or placebo Q6M (n¼ 18) for another 12months; or participants who received alendronate for 12months
followed by romosozumab 140mg monthly for 12 months (n¼ 41) and were rerandomized (1:1) to receive denosumab 60mg Q6M (n¼ 21) or placebo
(n¼ 20) for an additional 12 months. Data are means and bars indicate 95% CIs. aRandomized treatment group up to month 24. bRerandomized
treatment group at month 24. QM¼ every month; Q6M¼ every 6 months.
1402 MCCLUNG ET AL. Journal of Bone and Mineral Research
Adverse events potentially associated with injection site reactions
were observed more frequently with romosozumab than with
placebo (4.0% in the placebo group versus 5.9% in the
romosozumab 210mg QM group, and 15.3% in the combined
romosozumab groups throughmonth 24). These were reported as
mild, did not lead to study drug discontinuation or study
withdrawal, and were generally nonrecurring with continued
administration of romosozumab (subject incidence of injection site
reactions frommonth12 tomonth24: 0% in theplacebogroup, 0%
in the romosozumab210mgQMgroup, and 3.5% in the combined
romosozumab groups).
Through month 24 of treatment with romosozumab, binding
antibodies were identiﬁed in all the romosozumab groups
(14.3% to 32.1%; 15.7% in the romosozumab 210mgQMgroup),
including the alendronate 70mgQW/romosozumab 140mgQM
group (23.5%), with no apparent dose-related trend. Of these,
antibodies with in vitro neutralizing activity were reported in
3 (5.8%) participants in the romosozumab 140mg Q3M group,
4 (7.5%) in the romosozumab 210mg Q3M group, and 1 (2.0%)
in the romosozumab 210mg QM group. As previously
described, development of binding or neutralizing anti-
romosozumab antibodies appeared to have no effect on the
incidence of adverse events, pharmacokinetics, or
pharmacodynamics.(7)
Adverse events reported during the extension with denosu-
mab are shown in Table 3. The numbers of participants reporting
adverse events and serious adverse events were similar across all
groups that transitioned either to placebo or denosumab. None
of the serious adverse events led to discontinuation from the
study or investigational product in either treatment group. No
deaths occurred during year 3 of the study.
The subject incidence of fragility fractures from months 24 to
36 was 5 (3.9%) in the placebo group and 4 (3.2%) in the
denosumab group (Table 3). No vertebral fractures were
reported during months 24 to 36 in participants who
transitioned from romosozumab to placebo. Two participants
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Fig. 4. Percentage change from baseline in bone turnover markers through month 36. Results include only participants who had received
romosozumab 210mgQM (n¼ 40) for 24months and were then rerandomized (1:1) to receive denosumab 60mgQ6M (n¼ 20) or placebo Q6M (n¼ 20)
for another 12 months; participants who had received placebo (pooled) (n¼ 36) for 24 months and were rerandomized (1:1) to receive denosumab
60mgQ6M (n¼ 18) or placebo Q6M (n¼ 18) for another 12months; or participants who received alendronate for 12months followed by romosozumab
140mg monthly for 12 months (n¼ 41) and either denosumab 60mg Q6M (n¼ 21) or placebo (n¼ 20) for an additional 12 months. Data shown are
median changes in the bone-formation marker serum P1NP (A, C) and the bone-resorption marker serum b-CTX (B, D). Bars indicate interquartile ranges.
aRandomized treatment group up to month 24. bRerandomized treatment group at month 24. QM¼ every month; Q6M¼ every 6 months.
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who transitioned from romosozumab to denosumab had
reports of vertebral fractures; neither had received romosozu-
mab 210mg QM in the ﬁrst 2 years. No atypical fractures were
reported in any of the groups.
At month 36, the incidence of antibodies binding to
romosozumab was 25.1% (45/179) in participants who had
received romosozumab for the ﬁrst 24 months; of these, 3.4%
(6/179) were positive for romosozumab neutralizing antibodies.
In the group of participants who had received romosozumab
210mg QM, 7 (17.5%) and 1 (2.5%) had binding and neutralizing
antibodies, respectively. For participants who had received
alendronate for the ﬁrst 12 months and transitioned to
romosozumab from months 12 to 24, the incidence of
romosozumab binding antibodies was 18.4% (7/38), and none
developed romosozumab neutralizing antibodies.
Discussion
In this extension of the phase 2 study, we explored four
important questions related to treatment with romosozumab:
1) the efﬁcacy and safety of 24 months of treatment with
romosozumab, which is twice as long as the 12-month
treatment regimen evaluated in the phase 3 program; 2) the
response to romosozumab in patients who had taken
alendronate for 12 months; 3) the effects of discontinuing
therapy on BMD and bone turnover markers; and 4) the effect of
a follow-on treatment with denosumab after 2 years of
romosozumab.
Continuing romosozumab treatment for a second year
resulted in further increases in BMD at the lumbar spine and
proximal femur. However, the BMD increments during the
second year of romosozumab treatment were smaller than
those observed during the ﬁrst year, consistent with the bone
turnover marker results indicating reductions in indices of bone
formation and bone resorption during the second year of
romosozumab therapy. Thus, although there was incremental
beneﬁt in the second year of treatment without new safety
signals, the greatest beneﬁt of romosozumab was achieved in
the ﬁrst year of treatment in this phase 2 study. Based in part on
these observations, the phase 3 studies with romosozumab
were designed to evaluate the effect of therapy for 12 months
followed by anti-remodeling agents. In the recent report of the
FRAME study by Cosman and colleagues,(8) the risk of vertebral
fracture was reduced by 73% after 12 months of romosozumab
treatment compared with placebo, and by 75% with 12 months
of follow-on treatment with denosumab compared with the
group that received placebo for 12 months followed by
denosumab for 12 months. Similarly, in the ARCH study,(9)
romosozumab for 12 months followed by alendronate reduced
the risk of new vertebral fracture over 24 months (48%) and that
Table 2. Adverse Events With 24 Months of Romosozumab Therapy
Treatment group
Placebo
N¼ 50
n (%)
Romosozumab 210 mg QM
N¼ 51
n (%)
Romosozumab All dosesa
N¼ 255
n (%)
Any adverse eventb 48 (96.0) 48 (94.1) 245 (96.1)
Serious adverse event 9 (18.0) 6 (11.8) 36 (14.1)
Leading to study discontinuation 0 (0) 0 (0) 5 (2.0)
Death 1 (2.0) 0 (0) 1 (0.4)
Injection site reactionsc 2 (4.0) 3 (5.9) 39 (15.3)
Fragility fracturesd,e 1 (2.0) 1 (2.0) 1 (0.4)
QM¼ every month.
N¼number of participants who received 1 dose of investigational product.
aIncludes only participants who received romosozumab in the ﬁrst 12 months and continued to receive romosozumab up to 24 months.
bThe Medical Dictionary for Regulatory Activities v15.0 was used to code and report adverse events.
cAdverse events potentially associatedwith injection site reactions included any of the following events occurring at the injection site: pain, hematoma,
erythema, reaction, discomfort, hemorrhage, or rash.
dDeﬁned as all adverse events of fractures excluding locations in the skull, face, hand, foot, tooth, and excluding pathological fractures and fractures
associated with severe trauma or a fall from higher than the height of a stool, chair, ﬁrst rung on a ladder, or equivalent (>20 inches).
eOne subject in the placebo group had a radius fracture event and one subject in the romosozumab 210mgQMgroup had a radius fracture and an ulna
fracture on the same day.
Table 3. Adverse Events Starting in the Extension Phase (Month
24 to Month 36) Following Romosozumab Discontinuation and
Transition to Placebo or Denosumab
Treatment group
Placebo
N¼ 127
n (%)
Denosumab 60mg
Q6M
N¼ 125
n (%)
Any adverse eventa 96 (75.6) 99 (79.2)
Serious adverse event 7 (5.5) 8 (6.4)
Leading to study
discontinuation
2 (1.6) 0 (0)
Death 0 (0) 0 (0)
Injection site reactionb 0 (0) 1 (0.8)
Fragility fracturesc 5 (3.9) 4 (3.2)
Q6M¼ every 6 months.
N¼number of participants who received 1 dose of investigational
product.
aThe Medical Dictionary for Regulatory Activities v15.1 was used to
code and report adverse events.
bAdverse events potentially associated with injection site reactions
included any of the following events occurring at the injection site: pain,
hematoma, erythema, reaction, discomfort, hemorrhage, or rash.
cDeﬁned as all adverse events of fractures excluding locations in the
skull, face, hand, foot, tooth, and excluding pathological fractures and
fractures associated with severe trauma or a fall from higher than the
height of a stool, chair, ﬁrst rung on a ladder, or equivalent (>20 inches).
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of clinical (27%), nonvertebral (19%), and hip fractures (38%) at
the time of the primary analysis versus alendronate alone. The
risk reductions in new vertebral (37%) and clinical fractures
(28%), compared with alendronate, were already signiﬁcant
after 12 months.
Unlike the large increases in BMD at the lumbar spine and
total hip, BMD at the 1/3 radius site was not affected by
romosozumab therapy, whereas the small decrease observed in
the placebo group was somewhat attenuated by alendronate.
The clinical signiﬁcance of these observations is unclear
because, as stated above, romosozumab followed by alendro-
nate was signiﬁcantly more effective in reducing the risk of
nonvertebral and hip fractures than was therapy with alendr-
onate alone.(9)
The response to romosozumab 140mg QM in patients
previously treated with alendronate is of interest because
many patients who might be candidates for romosozumab will
have already received bisphosphonate therapy. The additional
gains in BMD observed in this group during the second year of
the study (5% at the lumbar spine and 0.7% at the total hip) were
only slightly less than observed in treatment-na€ıve women who
had received that dose of romosozumab during year 1 of the
study (5.5% and 1.3% in the lumbar spine and total hip,
respectively).(7) This is consistent with data from a recently
published study(10) where 12 months of treatment with
romosozumab 210mg QM, evaluated in phase 3 studies, was
compared with treatment with teriparatide 20mg daily in
participants transitioning from oral bisphosphonate and
showed greater increases in bone mass and bone strength
(by ﬁnite element analysis) than treatment with teriparatide.
In subjects who were treated with romosozumab for
24 months followed by denosumab for 12 months, markers of
bone remodeling decreased promptly and additional gains in
BMD at both the hip and spine were observed. The average BMD
increases frombaseline of 19.4% at the lumbar spine and 7.1% at
the total hip with 2 years of romosozumab 210mg QM followed
by 12 months of denosumab 60mg Q6M were similar to the
responses achieved with 6 to 8 years of denosumab therapy.(11)
Although direct comparisons cannot be made, these increases
also compare favorably with increases of approximately 15% at
the lumbar spine and 6% at the total hip in patients who
received teriparatide alone or in combination with denosumab
for 2 years followed by denosumab in the third year.(12)
As expected from the clinical pharmacology of romosozumab,
the inhibitory effects on markers of bone remodeling resolved
quickly upon discontinuation of therapy. P1NP, amarker of bone
formation, returned to the level observed in placebo-treated
patients, whereas b-CTX, a marker of bone resorption, increased
above pretreatment levels before returning toward baseline.
BMD at the lumbar spine and total hip declined toward baseline
after discontinuation. Similar responses were observed upon
discontinuation of blosozumab, a different humanized anti-
sclerostin antibody, after 12 months of treatment.(13) These data
are also similar to the rebound in bone turnover and rapid
decrease in BMD upon discontinuing non-bisphosphonate anti-
remodeling agents such as estrogen, denosumab, and odana-
catib, changes that are associated with rapid loss of vertebral
fracture protection.(14–18) Such results highlight the need for a
follow-on treatment with an anti-remodeling agent after
discontinuation of romosozumab to maintain or possibly
enhance the beneﬁts of the treatment, as was observed in the
subjects randomized to denosumab after stopping
romosozumab.
Other than mild injection site reactions, no important safety
issues related to therapy were identiﬁed in patients who
received 24 months of romosozumab or during the follow-on
year of denosumab therapy. This is similar to the safety proﬁle
noted in the much larger group of patients who received
12 months of romosozumab 210mg QM followed by 12 months
of denosumab therapy in the FRAME study.(8) Although
romosozumab-binding antibodies were detected, this occurred
predominately during the ﬁrst 12 months of therapy and was
not associatedwithmeasurable impairments of clinical response
or with adverse effects.
The major strength of our study is that it provides safety and
efﬁcacy data on treatment with romosozumab in women with
osteoporosis for up to 2 years and clinically relevant patterns of
sequential therapy with romosozumab and anti-remodeling
agents. However, the ﬁndings from this study should be
considered in the context of several limitations, including the
small sample sizes in the individual dosing groups, short follow-
up periods, use of surrogate outcomes (percentage changes in
BMD and bone turnover markers) for efﬁcacy evaluation, and
absence of a current best practice comparator group such as
3 years of a potent antiresorptive agent. In addition, the
comparator group treated with alendronate/romosozumab was
exposed to a lower dose of romosozumab (140mgQM) than the
group treated with romosozumab 210mg QM for 2 years.
Therefore, this study does not address the question of how the
sequence of a bisphosphonate followed by the recommended
dose of romosozumab 210mg QM compares with the use of an
equivalent dose of romosozumab only. However, in a recently
published study, patients were transitioned from bisphospho-
nate treatment to either romosozumab 210mg QM or
teriparatide 20mg once daily.(10) The BMD increases at the
spine and the hip were greater with romosozumab than with
teriparatide(10) but were smaller than those observed with
romosozumab 210mg QM in treatment-na€ıve populations.(7–9)
In summary, treatment with romosozumab in postmeno-
pausal women with low bone mass led to substantial and
continued increases in BMD over 2 years. The effects on BMD
were further augmented by follow-on therapy with denosumab.
Like other non-bisphosphonate drugs for osteoporosis, effec-
tiveness wanes within 1 year after discontinuing therapy,
suggesting that following romosozumab with an anti-remodel-
ing drug is important to maintain the skeletal response.
Romosozumab was well tolerated over a 2-year period, and
no safety issues were noted upon transitioning to denosumab.
These results support the use of romosozumab as a therapy for
postmenopausal women with osteoporosis.
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